| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/24/2006 | EP1104288B1 Orally disintegrable tablet forming a viscous slurry |
| 05/24/2006 | EP1019058B1 Pharmaceutical suspension comprising nevirapine hemihydrate |
| 05/24/2006 | EP1017836B1 Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof |
| 05/24/2006 | EP1015585B1 Tie ligand homologues |
| 05/24/2006 | EP0971699A4 Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| 05/24/2006 | EP0946147B1 Composition suitable for the treatment of equine laminitis |
| 05/24/2006 | EP0719295B1 Polymeric matrices and their uses in pharmaceutical compositions |
| 05/24/2006 | DE19543271B4 Orales pharmazeutisches Präparat An oral pharmaceutical composition |
| 05/24/2006 | DE10321165B4 Verfahren zur kontrollierten Abgabe von Wirkstoffen A method for the controlled release of active ingredients |
| 05/24/2006 | DE10248601B4 Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems A pharmaceutical composition for endonasal administration in the treatment of diseases and disorders of the central nervous system |
| 05/24/2006 | CN1777446A A medicament for the two-step perioperative therapy of solid tumours |
| 05/24/2006 | CN1777439A Somatostatin vectors |
| 05/24/2006 | CN1777431A Composition comprising alumina particles surface jointed with compound, transferring system and preparing method |
| 05/24/2006 | CN1777429A Prostaglandin compositions and applications for the treatment of vasospasm |
| 05/24/2006 | CN1777421A Composition for oral administration containing alkylene dioxybenzene derivative |
| 05/24/2006 | CN1777420A Processed fat composition for preventing/ameliorating lifestyle-related diseases |
| 05/24/2006 | CN1777411A Transmucosal drug delivery system |
| 05/24/2006 | CN1775946A Enhanced virus-mediated DNA transfer |
| 05/24/2006 | CN1775207A Esmolol formulation |
| 05/24/2006 | CN1775068A Compound palygorskite homing pigeon health-care sand |
| 05/24/2006 | CN1257186C Interferon gamma polypeptide variants |
| 05/24/2006 | CN1257011C Lipid nanocapsules, preparation method and use as medicine |
| 05/24/2006 | CN1256985C Method for manufacturing chitosan capillary and application thereof |
| 05/24/2006 | CN1256948C Avermectin containing parasite resisitant long-acting injection |
| 05/24/2006 | CN1256944C Preparation method of captopril compounding chitosan slow release micro ball |
| 05/24/2006 | CN1256943C Stable ascorbic acid inorganic salt liquid composition, its preparation method and applications |
| 05/24/2006 | CN1256939C Coenzyme Q10 containing microemulsion preconcentrates and microemulsions |
| 05/23/2006 | US7049360 Water-soluble or water-dispersible (co) polymers of hydroxyalkyl (meth) acrylates, a process for their preparation, and their use as coating agent, binder and/or film-forming excipient pharmaceutical dosage forms |
| 05/23/2006 | US7049345 Fat-binding polymers |
| 05/23/2006 | US7049339 comprises zinc sulphate, copper sulphate, an organic acid, an alkali metal salt; more effective at applying an active ingredient to a hoof than a conventional, non-colloid system; treatment of digital dermatitis |
| 05/23/2006 | US7049326 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots |
| 05/23/2006 | US7049321 Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor |
| 05/23/2006 | US7049316 Prodrugs of CC-1065 analogs |
| 05/23/2006 | US7049305 Bile-acid conjugates providing for sustained systemic concentration of drugs |
| 05/23/2006 | US7049298 Reacting Arg-Phe together with a reducing sugar to a Maillard reaction under condition sufficient to form the flavor active compound; useful for cosmetics, food and drugs |
| 05/23/2006 | US7049295 Compounds and use thereof to modify transport across cell membranes |
| 05/23/2006 | US7049286 Insulin conjugates and methods of use thereof |
| 05/23/2006 | US7049283 Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| 05/23/2006 | US7049144 Polymerizing in presence of drug/nucleic acid/DNA without modifying; for genetic transfer/expression in cells; drug delivery |
| 05/23/2006 | US7049136 Redirection of cellular immunity by receptor chimeras |
| 05/23/2006 | US7049061 use of R-2,4-diaminobutyric acid as a replacement for gamma-aminobutyric acid to make the hairpin loop; bind to the minor groove of a promoter region of a DNA sequence; tighter binding of the polyamides to the minor groove of DNA and also provides an amine function for derivatizing |
| 05/23/2006 | US7048951 applying mixtures of sodium nitrite, ascorbic acid and maleic acid, that generate nitric oxide on treatment with water, in the form of ointments for controlled release |
| 05/23/2006 | US7048950 Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications and preparations |
| 05/23/2006 | US7048947 Sustained-release preparation |
| 05/23/2006 | US7048946 Formulation for controlled release of drugs by combining hyrophilic and hydrophobic agents |
| 05/23/2006 | US7048945 Timed pulsatile drug delivery systems |
| 05/23/2006 | US7048943 Carotenoid-loaded liposomes |
| 05/23/2006 | US7048941 Chocolate composition as delivery system for nutrients and medications |
| 05/23/2006 | US7048940 alpha-pyrones in non-alcoholic beer, non-alcoholic wine and non-alcoholic distilled spirits as an effective carrier for the anticraving agents |
| 05/23/2006 | US7048938 somatotropin and a constituent that enhances bioavailability; superior efficacy for inducing weight gain and milk production |
| 05/23/2006 | US7048909 Aerosols containing nondegraded atenolol, pindolol, esmolol, propranolol, or metoprolol |
| 05/23/2006 | US7048908 Particles for inhalation having sustained release properties |
| 05/23/2006 | US7048907 Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products |
| 05/23/2006 | CA2428870C Freeze-dried pantoprazole preparation and pantoprazole injection |
| 05/23/2006 | CA2263921C Oral delayed immediate release formulation and method of preparation therefor |
| 05/23/2006 | CA2235413C Thermosensitive biodegradable polymers based on poly(ether-ester) block copolymers |
| 05/23/2006 | CA2227792C Polymeric drug formulations |
| 05/18/2006 | WO2006053006A2 Retinoid solutions and formulations made therefrom |
| 05/18/2006 | WO2006052734A1 Liposome formulation of peptide boronic acids compounds |
| 05/18/2006 | WO2006052733A1 Liposomal formulation of bortezomib (ps-341) |
| 05/18/2006 | WO2006052018A1 Aqueous ophthalmic suspension of crystalline rebamipide |
| 05/18/2006 | WO2006051819A1 Drug for external use and adhesive patch |
| 05/18/2006 | WO2006051818A1 Drug for external use and adhesive patch |
| 05/18/2006 | WO2006051805A1 MUTANT INTERFERON α PROTEINS AND USE THEREOF |
| 05/18/2006 | WO2006051732A1 Pharmaceutical preparation containing coated magnetic particles and method for production thereof, and diagnosis therapy system |
| 05/18/2006 | WO2006051572A2 Method for controlling the dimensions and the morphology of nanostructural polymeric materials, materials thereby obtained and uses thereof |
| 05/18/2006 | WO2006051241A2 Method for coupling non-immunogenic molecules, intermediate compound, final product obtained and uses thereof |
| 05/18/2006 | WO2006051227A1 Biomaterials carrying cyclodextrines having improved absorption properties and used for the progressive and delayed release of therapeutic molecules |
| 05/18/2006 | WO2006051198A1 Nanoparticles comprising an intracellular targeting element and preparation and use thereof |
| 05/18/2006 | WO2006050951A1 Novel composition for easing human child birth |
| 05/18/2006 | WO2006050930A2 Conjugates with enhanced cell uptake activity |
| 05/18/2006 | WO2006050631A1 Stabilized freeze-dried formulation for cephalosporin derivatives |
| 05/18/2006 | WO2005115333A3 A biomolecule-containing formulation of increased stability |
| 05/18/2006 | WO2005105037A3 Use of a viscoelastic composition for treating increased intraocular pressure |
| 05/18/2006 | WO2005097672A3 Method for the production of carbon nanotubes that are ferromagnetically filled in part and carry biomolecules, and use thereof in diagnosis and therapy |
| 05/18/2006 | WO2005092347A3 Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle |
| 05/18/2006 | WO2005058935A3 Aqueous suspensions of ciclesonide for nebulisation |
| 05/18/2006 | WO2005058283A3 Stabilised compositions of factor vii polypeptides |
| 05/18/2006 | WO2005012407A3 Polymer encapsulation of adenoviruses |
| 05/18/2006 | WO2004091533A3 Delivery systems of homogeneous, thermoreversible gel film containing kappa-2 carrageenan |
| 05/18/2006 | WO2004091532A3 Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
| 05/18/2006 | WO2002049619A9 Induced phase transition method for the production of microparticles containing hydrophilic active agents |
| 05/18/2006 | US20060106256 e.g. 1-[(benzylamino)methyl]-3-(3,5-difluorophenyl)-2-({3-[(dipropylamino)carbonyl]benzoyl}amino)propyl 4-nitrophenyl carbonate; secretase inhibitors; neurodegenerative disorders; Alzheimer's, Parkinson's diseases, Down syndrom, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type |
| 05/18/2006 | US20060106204 Bifunctional energy-reversible acyl-compositions |
| 05/18/2006 | US20060106197 comprises protein transduction domains; nuclear localization sequences; fusion proteins; for reversible immortalization of cells |
| 05/18/2006 | US20060106093 Formulation and delivery method to enhance antioxidant potency of Vitamin E |
| 05/18/2006 | US20060106090 Cytotoxic agents comprising taxanes and their therapeutic use |
| 05/18/2006 | US20060106057 Stabilization of quinapril using magnesium oxide |
| 05/18/2006 | US20060105994 Treatment of prostate cancer |
| 05/18/2006 | US20060105983 Cytotoxic agents |
| 05/18/2006 | US20060105982 Non-invasive gene targeting to ocular cells |
| 05/18/2006 | US20060105974 Conjugates of photosensitizers and oligonucleotides for selective photochemiotherapy |
| 05/18/2006 | US20060105955 Insulin entrapped within crystallized lecithin, including ascorbyl palmitate and lipoic acid, transdermal delivery |
| 05/18/2006 | US20060105948 GLP-2 derivatives |
| 05/18/2006 | US20060105429 Nucleic acid encoding protein which comprises hormone and has higher plasma stability; maintains biological activity for prolonged period in body |
| 05/18/2006 | US20060105378 Tenascin-C nucleic acid ligands |
| 05/18/2006 | US20060105046 Polymer conjugates of opioid antagonists |
| 05/18/2006 | US20060105042 axon regeneration kits comprising containers containing fibrinogen, thrombin, calcium chloride, poly/ADP-ribose/polymerase and N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboamide and drug delivery devices; kinase inhibitors |
| 05/18/2006 | US20060105040 Pharmaceutical tablet and process for making thereof |
| 05/18/2006 | US20060105037 Sustained release pharmaceutical preparations and methods for producing the same |